伊米达佐[2,1-b][1,3]氨酸衍生物作为阿尔法-同核素氨基酸聚合的潜在调节剂
Indrė Misiu Naitė1, Kamilė Mikalauskaitė2, Martyna Paulauskaitė1
1Institute of Chemistry, Faculty of Chemistry and Geosciences, Vilnius University, Naugarduko st. 24, Vilnius LT-03225, Lithuania.
ACS chemical neuroscience
|November 27, 2024
概括
新的伊米达佐[2,1-b][1,3]亚化合物抑制了α-synuclein聚合,这是帕金森病的关键因素. 这些小分子通过改变蛋白质聚合途径提供了潜在的治疗策略.
科学领域:
- 药用化学 医学化学
- 神经科学是一个神经科学.
- 生物化学 生物化学
背景情况:
- 粉样蛋白纤维在组织中的积累会导致粉样蛋白症.
- 帕金森病涉及阿尔法-同核素聚合.
- 目前帕金森病的治疗方法是控制症状,而不是阻止病情的进展.
研究的目的:
- 为了合成新的imidazo[2,1-b][1,3]thiazines.
- 为了识别抑制α-synuclein聚合的化合物.
- 探索潜在的帕金森病治疗方法的作用机制.
主要方法:
- 通过2-alkynylthioimidazoles的循环合成,以原子经济方式合成伊米达佐[2,1-b][1,3]亚.
- 使用10%AuCl的催化剂.
- 研究化合物对α-synuclein聚合途径的影响.
主要成果:
- 合成了几种imidazo[2,1-b][1,3]thiazine衍生物.
- 已识别的化合物抑制了α-synuclein聚合并改变了纤维细胞的形成.
- 化合物抑制了初级核和稳定了寡合物种.
结论:
- 伊米达佐[2,1-b][1,3]氨酸可以调节α-synuclein聚合.
- 这些化合物可能会导致帕金森病的新疗法.
- 开发小分子蛋白质聚合抑制剂的潜力.
相关概念视频
Antidepressant Drugs: MAOIs and Other Agents
194
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
194
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
2.6K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
2.6K
Aryldiazonium Salts to Azo Dyes: Diazo Coupling
2.9K
The reaction of weakly electrophilic aryldiazonium (also called arenediazonium) salts with highly activated aromatic compounds leads to the formation of products with an —N=N— link, called an azo linkage. This reaction, presented in Figure 1, is known as diazo coupling and occurs without the loss of the nitrogen atoms of the aryldiazonium salt. Highly activated aromatic compounds such as phenols or arylamines favor the diazo coupling reaction. The coupling generally occurs at the...
2.9K
Drugs Affecting Neurotransmitter Release or Uptake
952
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
952
Alzheimer's Disease: Treatment
165
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
165
Drugs Affecting Neurotransmitter Synthesis
1.3K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.3K


